Resumen

GSK has in-licensed a novel NNRTI-class candidate (GSK2248761, IDX12899) for the treatment of subjects with HIV-1 infection from Idenix Pharmaceuticals. Idenix Pharmaceuticals completed a proof-of-concept study evaluating GSK2248761 monotherapy over seven days in forty treatment-naïve subjects infected with HIV-1. GSK2248761 doses sequentially evaluated were 800 mg QD, 400 mg QD, 200 mg QD and 100mg QD. This study will evaluate a lower dose, or doses, of GSK2248761 to better characterize the dose-response and concentration-response curves. The results from this study will be used to select doses for future clinical studies in HIV-1 infected subjects.

Elegibilidad

Edad mínima: 21 YearsEdad máxima: 65 YearsSexo: ALL

Criterios de inclusión

Male or Female, 21 to 65 years of age.
Female of non-childbearing potential defined as: being post-menopausal, defined as 12 months of spontaneous amenorrhea and having a serum FSH level \>40 MIU/ml at Screening OR have had a documented bilateral tubal ligation or hysterectomy of at least 6 months prior to study initiation, bilateral oophorectomy or bilateral tubal ligation.
Plasma HIV-1 RNA value \>= 5000 copies/mL.
CD4+ count \>= 200 cells/mm3.
Is antiretroviral treatment-naïve and agrees not to start antiretroviral therapy prior to clinic check-in (Day-1).
Subject agrees to start a standard HAART regimen on Day 8 of the study or Kaletra monotherapy for 28 days within 24 hours after the last dose of study medication.
Capable of giving written informed consent, which includes being willing and able to comply with the requirements and restrictions listed in the consent form.

Criterios de exclusión

Subject is pregnant as determined by a positive urine/serum pregnancy test at Screening and Day -1.
Lactating females.
Male subjects of reproductive potential and unwilling to use double barrier method of contraception (e.g., condom plus spermicide) and continue to use an adequate method of birth control for at least 30 days after the last dose of the study drug.
Has a positive screening Hepatitis B surface antigen, positive screening Hepatitis C virus (HCV) antibody and detectable HCV ribonucleic acid (RNA) on subsequent testing. If the Hepatitis C antibody is positive but the HCV RNA is undetectable, the subject may be included in the study.
History of regular alcohol consumption within 6 months of Screening as defined as: an average weekly intake of \>21 units for males or \>14 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (\~240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits
Has a positive pre-study drug screen. Drugs that will be screened for include amphetamines, barbiturates, cocaine and PCP.
History of sensitivity to any of the study medications, or components thereof, or a history of drug or other allergy that, in the opinion of the Principal Investigator, contraindicates their participation. In addition, if heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.
Note: Study drugs include GSK2248761 placebo or the follow-up HAART or Kaletra therapy.
Received an immunomodulating agent (e.g., interleukin-2) or immunotherapeutic vaccine within 30 days before Day -1.
Requires a medication that is a known substrate, inhibitor and/or inducer of CYP3A4.
Has received an investigational drug or participated in any other research trial within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dosing day.
Has ever had an AIDS-defining illness.
Has a history of or has a currently active clinically important disease other than HIV-1 infection that, in the opinion of the Investigator, may put the subject at risk because of participation in this study (including renal and hepatic impairment, active infections including tuberculosis or opportunistic infection, malignancy and cardiac dysfunction).
Has an intestinal malabsorption (e.g., structural defects, digestive failure, enzyme deficiencies, etc).
Has a pre-existing NNRTI drug resistance based on genotyping at Screening.
Where participation in the study would result in donation of blood or blood products in excess of 500mL within a 56 day period.
Subject has any of the following laboratory parameters at Screening (a single repeat is allowed for eligibility determination): Hemoglobin \<8.5 g/dL, Neutrophil count \<1000 cells/mm3, Platelet count \<100,000 cells/mm3, Serum creatinine \> the upper limit of normal (ULN), AST or ALT \<= 2.5 x ULN.

Intervenciones

drug

GSK2248761

GSK2248761 30 mg capsule once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.

drug

Lopinavir/ritonavir

Lopinavir 400 mg and ritonovir 100 mg every 12 hours for 28 days. Lopinavir/ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class. Kaletra is a trademark of Abbott Laboratories.

drug

HAART

Highly Active Antiretroviral therapy of the doctor's choice.

drug

Placebo

Placebo is a capsule with no drug in it.

drug

GSK2248761

GSK2248761 10 mg -20 mg or 40 mg - 90 mg once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.

A Proof of Concept Study for GSK2248761 (An Extension of NV-05A-002: A Phase I/IIa Double-Blind Study to Evaluate the Safety and Tolerability, Antiretroviral Activity, Pharmacokinetics and Pharmacodynamics of IDX12899 in Antiretroviral Treatment-Naive HIV-1 Infected Subjects, Completed by Idenix)

Resumen

Elegibilidad

Criterios de inclusión

Criterios de exclusión

Intervenciones

GSK2248761

Lopinavir/ritonavir

HAART

Placebo

GSK2248761

Ubicaciones

GSK Investigational Site

Patrocinadores